2023-11-14T08:12:31-06:00 2022-12-31 871353108 EISNER ADVISORY GROUP LLC 733 THIRD AVENUE NEW YORK NY 100172703 990 2022-01-01 981051444 GLOBAL HEALTH INVESTMENT CORPORATION GLOB 6467551981 500 FIFTH AVENUE SUITE 5120 NEW YORK NY 10110 LABEEB ABBOUD CHAIRMAN AND CEO 6467751981 2023-11-10 1 LABEEB ABBOUD 999009999 1 WILLIAM EPSTEIN P01307171 2129498700 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z X LABEEB ABBOUD 500 FIFTH AVENUE SUITE 5120 NY NY 10010 69598791 0 X WWW.GHICFUNDS.ORG X 2012 DE THE CORPORATION IS ORGANIZED AND SHALL BE OPERATED EXCLUSIVELY FOR SOCIAL (CONTINUED SCHEDULE O) (CONTINUED FROM FORM 990, PAGE 1 PART I) WELFARE PURPOSES WITHIN THE MEANING OF SECTION 501(C)(4) OF THE INTERNAL REVENUE CODE OF 1986, AS IT BE AMENDED, INCLUDING THE RELIEF OF THE POOR AND DISTRESSED OR OF THE UNDERPRIVILEGED; THE PROMOTION OF SOCIAL WELFARE AND THE LESSENING OF THE BURDENS OF GOVERNMENT. IN FURTHERANCE OF THESE PURPOSES, THE CORPORATION MAY SEEK WAYS TO PROVIDE AFFORDABLE FINANCING TO SUPPORT THE DEVELOPMENT OF THERAPEUTIC DRUGS & TREATMENTS, VACCINES, PREVENTATIVES, DIAGNOSTICS, AND OTHER TECHNOLOGIES, PRODUCTS OR SERVICES TO ADDRESS GLOBAL HEALTH CHALLENGES, INCLUDING WITHOUT LIMITATION, SUPPORTING THE DEVELOPMENT OF MEDICAL COUNTERMEASURES AND TECHNOLOGIES THAT CAN HELP ADDRESS THREATS TO GLOBAL HEALTH SECURITY, ALL TO PROMOTE THE SOCIAL WELFARE OF ALL POPULATIONS. 4 3 0 0 0 0 16598000 68766234 0 70556 249889 762001 0 0 16847889 69598791 0 0 0 0 871668 2512026 0 0 0 551401 1575474 1423069 4087500 15424820 65511291 106183994 172792060 471532 7506598 105712462 165285462 X THE MISSION OF THE GLOBAL HEALTH INVESTMENT CORPORATION IS TO CATALYZE THE DEVELOPMENT OF TECHNOLOGIES TO IMPROVE GLOBAL HEALTH AND HEALTH EQUITY, AND STRENGTHEN GLOBAL HEALTH SECURITY. THE ORGANIZATION SEEKS TO ADVANCE ITS MISSION BY (CONTINUED SCHEDULE O) 0 0 3270000 0 70556 ACHIEVING FINANCIAL CLOSE OF THE GLOBAL HEALTH INVESTMENT FUND I ON 19 DECEMBER 2013, WITH CAPITAL COMMITMENTS OF $108,365,000. THE ORGANIZATION SERVES AS GENERAL PARTNER/MANAGING MEMBER OF THE GLOBAL HEALTH INVESTMENT FUND, AND ALSO PROVIDED A CAPITAL COMMITMENT TO THE FUND ALONGSIDE THE OTHER LIMITED PARTNERS. THE FUND'S CAPITAL WAS INVESTED INTO TWELVE PORTFOLIO INVESTMENTS DURING YEARS 2012-2018. THE ORGANIZATION MANAGED THE FUND'S PORTFOLIO COMPANY INVESTMENTS, RESULTING IN REVENUE TO THE FUND AND DISTRIBUTIONS TO THE ORGANIZATION AND THE OTHER LIMITED PARTNERS OF THE FUND. (CONTINUED SCHEDULE O) (CONTINUED FROM PART III, 4A) IN 2019, THE ORGANIZATION MADE AN INVESTMENT AS LIMITED PARTNER IN THE ADJUVANT CAPITAL GLOBAL HEALTH INVESTMENT FUND DE, IN THE AMOUNT OF $22 MILLION.IN 2021, THE ORGANIZATION MADE AN INVESTMENT AS LIMITED PARTNER IN THE WOMEN'S AND CHILDREN'S HEALTH TECHNOLOGY FUND, IN THE AMOUNT OF $10 MILLION. THE ORGANIZATION ENTERED INTO A TEN-YEAR AGREEMENT WITH U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE'S BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA") TO CARRY OUT ACTIVITIES THAT FOSTER AND ACCELERATE THE DEVELOPMENT AND INNOVATION OF MEDICAL COUNTERMEASURES. THE AGREEMENT, UNLIKE TYPICAL FEE FOR SERVICE OR COST REIMBURSEMENT PROCUREMENT GRANTS, WAS STRUCTURED AS AN OTHER TRANSACTION AGREEMENT ("OTA") OF WHICH BARDA, WITH THE AUTHORITY UNDER APPLICABLE LAW, MAY ENTER INTO TRANSACTIONS OTHER THAN PROCUREMENT CONTRACTS, GRANTS, COOPERATIVE AGREEMENTS, AND ARE NOT SUBJECT TO FEDERAL ACQUISITION REGULATION. DURING 2021, THE ORGANIZATION RECEIVED $16.6 MILLION IN FUNDING FROM BARDA UNDER THE OTA, FOR ACTIVITIES TO BE CONDUCTED BY THE ORGANIZATION PURSUANT TO THE OTA. THE ORGANIZATION ESTABLISHED A WHOLLY OWNED DELAWARE LIMITED LIABILITY COMPANY, THE GHIC GLOBAL HEALTH SECURITY PORTFOLIO, LLC (THE "GHS PORTFOLIO LLC"), TO MAKE VENTURE INVESTMENTS IN BIOTECHNOLOGY COMPANIES AND OTHER ORGANIZATIONS DEVELOPING TECHNOLOGIES THAT FALL WITHIN THE MISSION SCOPE OF THE OTA ACTIVITIES. IN 2021, THE ORGANIZATION MADE ITS INITIAL INVESTMENT WITH BARDA FUNDING, THROUGH THE GHS PORTFOLIO LLC, IN THE PRIVATE EQUITY SECURITIES OF BIOLINQ. IN 2022, THE ORGANIZATION RECEIVED AN ADDITIONAL $68.8 MILLION IN FUNDING FROM BARDA PURSUANT TO THE OTA. THE ORGANIZATION ALSO ENTERED INTO A STRATEGIC COLLABORATION ARRANGEMENT WITH THE MITRE CORPORATION, PURSUANT TO WHICH MITRE AGREED TO PROVIDE THE ORGANIZATION WITH UP TO $10 MILLION TO BE CO-INVESTED BY GHIC, ALONGSIDE BARDA PROVIDED FUNDING, IN VENTURE INVESTMENTS MADE BY THE ORGANIZATION PURSUANT TO THE OTA. DURING THE COURSE OF 2022, THE ORGANIZATION (THROUGH THE GHS PORTFOLIO LLC) MADE TEN INVESTMENTS OF PRIVATE EQUITY SECURITIES IN BIOTECHNOLOGY COMPANIES WITH BARDA AND MITRE PROVIDED CAPITAL. AT DECEMBER 31, 2022, THE TOTAL AMOUNT INVESTED BY THE GHS PORTFOLIO LLC IN THE ELEVEN PORTFOLIO COMPANY INVESTMENTS WAS $39 MILLION. 3270000 0 1 0 0 0 0 0 0 0 0 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 1 X 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X EVELYN YANATOS 5164486106 500 FIFTH AVENUE SUITE 5120 NEW YORK NY 10110 LABEEB M ABBOUD CHAIRMAN AND CEO 40.00 0.00 X X 700099 0 62207 KAI GESING DIRECTOR 1.00 0.00 X 0 0 0 WILLIAM GREENE DIRECTOR (THU JUNE 2022) 1.00 0.00 X 21542 0 0 GEORGE W WELLDE JR DIRECTOR 1.00 0.00 X 15000 0 0 PAUL KLINGENSTEIN DIRECTOR 1.00 0.00 X 0 0 0 EVELYN YANATOS TREASURER AND SECRETARY 10.00 0.00 X 113070 0 515 OLAYINKA FAGBAYI VICE PRESIDENT 40.00 0.00 X 300000 0 35348 CHARLES JEFFREY PETTY MANAGING DIRECTOR 40.00 0.00 X 286364 0 39977 DAMIEN ZADOUR SOGHOIAN VENTURE PARTNER 40.00 0.00 X 281061 0 32177 1717136 0 170224 5 0 1 0 PRYOR CASHMAN LLP 500 5TH AVE STE 5120 NEW YORK NY 10110 LEGAL 174913 1 68766234 68766234 MANAGEMENT FEE 900099 70556 70556 70556 762001 762001 69598791 70556 0 762001 X 862423 689939 172484 1611238 1288991 322247 -71770 -57417 -14353 26993 21595 5398 83142 66513 16629 764837 611870 152967 67654 67654 419632 389829 29803 1458 1166 292 150444 120355 30089 13445 10756 2689 44623 35698 8925 69415 55532 13883 43966 35173 8793 4087500 3270000 817500 0 59729499 93666966 3998000 0 75568 42453632 77629758 2863 1419768 106183994 172792060 471532 826997 0 6679601 471532 7506598 X 53782149 45671544 51930313 119613918 105712462 165285462 106183994 172792060 65511291 -5938291 0 X 0 1 X 0 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 GLOBAL HEALTH INVESTMENT FUND 24310663 F ADJUVANT GLOBAL HEALTH TECHNOLOGY 13267266 F BIOLINQ INCORPORATED 4999998 F MICRON BIOMEDICAL INC 6250000 F ENDPOINT HEALTH INC 5000000 F MONOD BIO INC 5000000 F UNIVERCELLS SA 4670500 F VACCINE COMPANY INC 3977499 F THE PUBLIC HEALTH COMPANY GROUP INC 999999 F NATIONAL RESILIENCE INC 692322 F VAXESS TECHNOLOGIES INC 2000000 F CENTIVAX, INC 5000000 F BUGSEQ BIOINFORMATICS INC 500000 F WOMEN'S AND CHILDREN'S HEALTH TECHNOLOGY EU FUND SCSP 961511 F 77629758 DUE TO INVESTOR 6679601 6679601 X 63660500 -5938291 -5938291 69598791 0 69598791 4087500 0 4087500 0 4087500 PART X, LINE 2: THE CORPORATION IS SUBJECT TO THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (THE "FASB") ACCOUNTING STANDARD CODIFICATION ("ASC") TOPIC 740, INCOME TAXES, AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME-TAX OBLIGATIONS. FOR THE CORPORATION, THESE PROVISIONS COULD BE APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME. BECAUSE OF THE CORPORATION'S GENERAL TAX EXEMPT STATUS, MANAGEMENT BELIEVES ASC TOPIC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON THE CORPORATION'S CONSOLIDATED FINANCIAL STATEMENTS. X X X X X 0 0 0 0 0 0 0 0 0 LABEEB M ABBOUD CHAIRMAN AND CEO 500099 0 200000 0 0 0 50010 0 12197 0 762306 0 0 0 OLAYINKA FAGBAYI VICE PRESIDENT 275000 0 25000 0 0 0 28302 0 7046 0 335348 0 0 0 CHARLES JEFFREY PETTY MANAGING DIRECTOR 286364 0 0 0 0 0 28636 0 11341 0 326341 0 0 0 DAMIEN ZADOUR SOGHOIAN VENTURE PARTNER 281061 0 0 0 0 0 28106 0 4071 0 313238 0 0 0 PART I, LINE 3 COMPENSATION FOR THE ORGANIZATION'S CEO HAS BEEN DETERMINED USING INDEPENDENT COMPENSATION CONSULTANTS, REVIEW OF FORMS 990 FROM COMPARABLE ORGANIZATIONS, VERIFIED AGAINST INDUSTRY COMPENSATION SURVEYS AND APPROVED BY THE BOARD THROUGH A WRITTEN EMPLOYMENT CONTRACT. THE PRECEDING MAY BE DONE FROM TIME TO TIME AS NEEDED. PART III, QUESTION 1, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS, MISSION (CONTINUED FROM PART III , LINE 1) MANAGING FUNDING VEHICLES, MAKING INVESTMENTS OR PROVIDING FUNDING DESIGNED TO SUPPORT THE DEVELOPMENT, PRODUCTION, AND COMMERCIALIZATION OF DRUGS, VACCINES, PREVENTATIVES, DIAGNOSTICS, AND OTHER RELATED TECHNOLOGIES, OR OTHER SERVICES. THE TECHNOLOGIES FINANCED TARGET GLOBAL HEALTH AND GLOBAL HEALTH SECURITY CHALLENGES, INCLUDING BUT NOT LIMITED TO: (I) INFECTIOUS DISEASES THAT CAUSE SIGNIFICANT MORBIDITY AND MORTALITY GLOBALLY, WITH A PARTICULAR FOCUS ON DEVELOPING COUNTRIES, (II) REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH ISSUES, PARTICULARLY THOSE THAT DISPROPORTIONATELY IMPACT DEVELOPING COUNTRIES, AND (III) THE DEVELOPMENT OF MEDICAL COUNTERMEASURES AND TECHNOLOGIES THAT CAN HELP ADDRESS THREATS TO GLOBAL HEALTH SECURITY, TO PROMOTE THE SOCIAL WELFARE OF ALL POPULATIONS. FORM 990, PART I, LINE 5, & PART V, LINE 2A AND B THE ORGANIZATION USES A PROFESSIONAL EMPLOYER ORGANIZATION (PEO) FOR THE FILING OF FORM W-2. AS SUCH, THE ORGANIZATION ITSELF DOES NOT ISSUE ANY FORMS W-2 USING ITS EIN. THE ORGANIZATION DOES, HOWEVER, HAVE 6 EMPLOYEES WHO RECEIVE W-2S THROUGH THE PEO PAYMASTER. THE ORGANIZATION ENSURES THAT THE PEO FILES ALL REQUIRED FEDERAL EMPLOYMENT TAX RETURNS. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS THREE DIRECTOR MEMBERS WITH EQUAL VOTING RIGHTS. THEY HAVE THE POWER TO ELECT OR APPOINT OTHER DIRECTOR MEMBERS. FORM 990, PART VI, SECTION A, LINE 7A THE ORGANIZATION HAS THREE DIRECTOR MEMBERS WITH EQUAL VOTING RIGHTS. THEY HAVE THE POWER TO ELECT OR APPOINT OTHER DIRECTOR MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B THIS FORM WAS REVIEWED AND APPROVED BY THE ORGANIZATION'S BOARD OF DIRECTOR'S AUDIT COMMITTEE, WHICH PERFORMS THIS FUNCTION ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 12C THESE DETAILS ARE DISCUSSED AT PERIODIC BOARD AND OTHER MEETINGS THROUGHOUT THE YEAR. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE ORGANIZATION'S CEO HAS BEEN DETERMINED USING INDEPENDENT COMPENSATION CONSULTANTS, REVIEW OF FORMS 990 FROM COMPARABLE ORGANIZATIONS, VERIFIED AGAINST INDUSTRY COMPENSATION SURVEYS AND APPROVED BY THE BOARD THROUGH A WRITTEN EMPLOYMENT CONTRACT. THE PRECEDING MAY BE DONE FROM TIME TO TIME AS NEEDED. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICTS OF INTEREST POLICIES AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST TO OUR MEMBERS AND THE PUBLIC AT LARGE. FORM 990, PART IX, LINE 11G OTHER CONSULTING: PROGRAM SERVICE EXPENSES 389,829. MANAGEMENT AND GENERAL EXPENSES 29,803. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 419,632. GHIC GLOBAL HEALTH SECURITY PORTFOLIO LLC 500 FIFTH AVENUE SUITE 5120 NY NY 10010 882361986 INVESTMENT FUND FOR GLOBAL HEALTH RESEARCH DE 0 39090318 GLOBAL HEALTH INVESTMENT CORPORATION GLOBAL HEALTH INVESTMENT FUND 500 FIFTH AVENUE SUITE 5120 NY NY 10010 981051448 INVESTMENT FUND FOR GLOBAL HEALTH RESEARCH DE GLOBAL HEALTH INVESTMENT CORPORATION STATUTORILY EXEMPT 24310663 0 1 0.12240 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 GHIC GLOBAL HEALTH SECURITY PORTFOLIO LLC B 35756986 FV GLOBAL HEALTH INVESTMENT FUND C 0 FV ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE LP 501 5TH AVE SUITE 1404 NY NY 10017 832182505 INVESTMENT FUND FOR GLOBAL HEALTH RESEARCH DE STATUTORILY EXEMPT 0 0 13267266 0 0 0.46220 WOMEN'S AND CHILDREN'S HEALTH TECHNOLOGY EU FUND SCSP 501 5TH AVE SUITE 1404 NY NY 10017 INVESTMENT FUND FOR GLOBAL HEALTH RESEARCH DE STATUTORILY EXEMPT 0 0 961511 0 0 0.62000